Daily orforglipron tablets led to greater weight loss than semaglutide tablets, offering potential oral alternative to Wegovy and Mounjaro

A new daily pill could be a more effective GLP-1 tablet for weight loss, according to a clinical trial that may pave the way for a non-injection alternative to Wegovy and Mounjaro.

The drug, called orforglipron and manufactured by Eli Lilly, is prescribed for type 2 diabetes and targets the same GLP-1 receptors as oral semaglutide. Like semaglutide, it lowers blood sugar levels, slows digestion and suppresses appetite. However, unlike semaglutide tablets, it does not need to be taken on an empty stomach.